LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Начало・Списък с акции・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Отворен

Сектор Здравеопазване

471.32 0.13

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

467.68

Максимум

474.62

Ключови измерители
By Trading Economics
Приходи	-4.7B -3.6B
Продажби	-40M 2.7B
P/E Средно за сектора	30.09 104.138
EPS	-12.83
Марж на печалбата	-135.608
Служители	5,400
EBITDA	1.3B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+9.34 upside

Дивиденти
By Dow Jones
Следващи печалби	4.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-41M 122B
Предишно отваряне	471.19
Предишно затваряне	471.32

Настроения в новините

By Acuity

80%

20%

362 / 390 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

474.91 / 477.66 Подкрепа & съпротива

Vertex Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.08.2024 г., 20:45 ч. UTC

Печалби

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

6.05.2024 г., 20:37 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug

10.04.2024 г., 22:48 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

10.04.2024 г., 21:40 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.

10.04.2024 г., 21:24 ч. UTC

Придобивния, сливания и поглъщания

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10.04.2024 г., 20:30 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

26.09.2024 г., 14:20 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

1.08.2024 г., 20:30 ч. UTC

Печалби

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1.08.2024 г., 20:03 ч. UTC

Печалби

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1.08.2024 г., 20:02 ч. UTC

Печалби

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1.08.2024 г., 20:02 ч. UTC

Печалби

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

27.06.2024 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Vertex Also Sees About $200M of Transaction-Related Compensation Expense Associated With Acceleration of Unvested Awards Pursuant to Alpine Equity Incentive Plans

27.06.2024 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Vertex Pharmaceuticals Expects to Record About $4.4B One-Time Acquired In-Process R&D Expense Related to May Purchase of Alpine Immune Sciences

6.05.2024 г., 21:00 ч. UTC

Печалби

Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD

6.05.2024 г., 20:15 ч. UTC

Печалби

Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD

6.05.2024 г., 20:03 ч. UTC

Печалби

Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX

6.05.2024 г., 20:03 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX

6.05.2024 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Net $1.1B >VRTX

6.05.2024 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX

6.05.2024 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX

23.04.2024 г., 18:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk

11.04.2024 г., 20:18 ч. UTC

Придобивния, сливания и поглъщания

Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD

11.04.2024 г., 16:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Alpine Deal Seen Giving Vertex New Expertise -- Market Talk

11.04.2024 г., 14:46 ч. UTC

Придобивния, сливания и поглъщания

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

11.04.2024 г., 13:47 ч. UTC

Горещи акции

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

10.04.2024 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10.04.2024 г., 21:09 ч. UTC

Придобивния, сливания и поглъщания

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update

10.04.2024 г., 20:46 ч. UTC

Придобивния, сливания и поглъщания

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD

10.04.2024 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B

10.04.2024 г., 20:04 ч. UTC

Придобивния, сливания и поглъщания

Alpine Immune Sciences: Vertex Will Acquire Alpine for $65 Per Shr or Approximately $4.9B in Cash, Transaction Approved by Both Boards of Directors, Anticipated to Close in 2Q >ALPN

Сравнение с други в отрасъла

Ценова промяна

Vertex Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

9.34% нагоре

12-месечна прогноза

Среден 515.11 USD 9.34%

Висок 600 USD

Нисък 361 USD

Според 26 анализатори от Wall Street, предложили 12-месечна ценова цел за Vertex Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

26 ratings

Купи

Задържане

Продай

Според 26 анализатори, дали борсови рейтинги на Vertex Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

474.91 / 477.66Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

362 / 390 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.